Cytokinetics (NASDAQ:CYTK) used its presentation at Citi’s Life Sciences Conference to highlight the recent U.S. approval of its first drug, Myqorzo, and to preview an upcoming Phase 3 readout in non- ...

SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...

Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the ...

ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...

SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 ...

New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten)SOUTH SAN FRANCISCO, ...

– Topline Phase 2 data from the IMPROVE-ISCHEMIA clinical trial in Stable Angina also anticipated in 4Q 2023 – BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, ...

BOSTON--(BUSINESS WIRE)--Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart ...

MYQORZO® (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention ...